ArticleBiomolecules2026
Hydrogel-Delivered Recombinant Fibronectin DK1 Promotes Diabetic Wound Healing by Boosting Cellular Responses.
Article in Biomolecules, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Diabetic wounds remain a major clinical challenge due to persistent inflammation, impaired angiogenesis, and delayed tissue regeneration. Fibronectin plays a crucial role in regulating cellular responses during wound repair, yet the therapeutic potential of recombinant fibronectin functional domains remains insufficiently explored. In this study, three recombinant fibronectin variants (D89, D8910, and DK1) were successfully designed, expressed, and purified. Among them, DK1 exhibited superior biological activity, significantly enhancing cell proliferation, adhesion, and migration in vitro. To improve its therapeutic efficacy, recombinant DK1 was incorporated into a biocompatible hydrogel delivery system. The DK1-loaded hydrogel demonstrated excellent cytocompatibility, antioxidant, and antibacterial properties. In a diabetic mouse wound model, hydrogel-mediated delivery of DK1 significantly accelerated wound closure. Histological and immunohistochemical analyses further revealed that DK1 promoted wound repair by enhancing re-epithelialization, improving collagen deposition and remodeling, reducing inflammatory responses, and stimulating angiogenesis. These findings demonstrate that recombinant fibronectin DK1 enhances cellular responses and effectively promotes diabetic wound healing, highlighting its potential as a promising biomolecular therapeutic strategy for chronic wound treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.